{
    "nct_id": "NCT03144765",
    "official_title": "Multicenter Phase II Study of Transanal Total Mesorectal Excision (taTME) With Laparoscopic Assistance for Rectal Cancer",
    "inclusion_criteria": "* New diagnosis of histologically confirmed adenocarcinoma of the rectum\n* Age ≥18\n* Clinical stage cT1 (high-risk), T2, or T3, cN0, N1, N2 on staging pelvic MRI\n* Negative predicted CRM on staging pelvic MRI\n* No evidence of metastasis on CT scans of the chest, abdomen and pelvis\n* Rectal cancer located within 10 cm from the anal verge based on proctoscopy and digital rectal examination (DRE)\n* Complete preoperative colonoscopy demonstrating no synchronous colon cancer\n* Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)\n* Eligible to undergo laparoscopic or robotic LAR with or without a temporary diverting stoma, based on multidisciplinary tumor board consensus\n* Able to understand and willing to sign a written informed consent form\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* cT4 on staging pelvic MRI\n* >12 weeks delay between completion of neoadjuvant CRT and planned study procedure\n* Severely symptomatic rectal tumors\n* Tumors invading into the internal anal sphincter muscle based on DRE and pelvic MRI\n* Fecal incontinence at baseline\n* Prior history of rectal resection\n* Prior history of colorectal cancer\n* History of inflammatory bowel disease\n* Uncontrolled concurrent illness\n* Pregnancy\n* Subjects who cannot read or understand English",
    "miscellaneous_criteria": ""
}